NASDAQ:FATE - Fate Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$10.85 -0.35 (-3.13 %)
(As of 08/20/2018 04:00 PM ET)
Previous Close$11.21
Today's Range$10.80 - $11.21
52-Week Range$2.81 - $14.45
Volume13,407 shs
Average Volume640,730 shs
Market Capitalization$614.32 million
P/E Ratio-10.84
Dividend YieldN/A
Beta1.57
Fate Therapeutics logoFate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; FT500 induced pluripotent stem cells (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516 engineered iPSC-derived NK cell product candidate for the treatment of hematologic/solid tumors; and FT819 engineered chimeric antigen receptor 19 iPSC-derived T-cell product candidate for hematologic/solid tumors. The company's immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; ToleraCyte for the treatment of autoimmune and inflammatory diseases; and FT300 iPSC-derived myeloid derived suppressor cell product candidate for the treatment of autoimmune diseases. Fate Therapeutics, Inc. has a research collaboration and license agreement with Memorial Sloan Kettering Cancer Center to develop off-the-shelf engineered T-cell product candidates; a research collaboration partnership with the University of California San Diego to develop off-the-shelf chimeric antigen receptor-targeted natural killer cell cancer immunotherapies. It also has a strategic research collaboration and license agreement with Juno Therapeutics, Inc. to identify small molecule modulators that enhance the function of T cells. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.

Receive FATE News and Ratings via Email

Sign-up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FATE
CUSIPN/A
Phone858-875-1800

Debt

Debt-to-Equity Ratio0.25
Current Ratio4.92
Quick Ratio4.92

Price-To-Earnings

Trailing P/E Ratio-10.84
Forward P/E Ratio-8.97
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.11 million
Price / Sales141.02
Cash FlowN/A
Price / CashN/A
Book Value$1.51 per share
Price / Book7.19

Profitability

EPS (Most Recent Fiscal Year)($1.02)
Net Income$-42,950,000.00
Net Margins-1,387.53%
Return on Equity-95.07%
Return on Assets-64.28%

Miscellaneous

Employees80
Outstanding Shares53,420,000
Market Cap$614.32 million

Fate Therapeutics (NASDAQ:FATE) Frequently Asked Questions

What is Fate Therapeutics' stock symbol?

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

How were Fate Therapeutics' earnings last quarter?

Fate Therapeutics Inc (NASDAQ:FATE) announced its quarterly earnings results on Monday, August, 6th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by $0.05. The biopharmaceutical company earned $1 million during the quarter, compared to the consensus estimate of $1.02 million. Fate Therapeutics had a negative net margin of 1,387.53% and a negative return on equity of 95.07%. The company's quarterly revenue was up .0% on a year-over-year basis. View Fate Therapeutics' Earnings History.

When is Fate Therapeutics' next earnings date?

Fate Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 7th 2018. View Earnings Estimates for Fate Therapeutics.

What price target have analysts set for FATE?

9 brokers have issued 12-month price targets for Fate Therapeutics' stock. Their predictions range from $7.00 to $20.00. On average, they anticipate Fate Therapeutics' share price to reach $16.7143 in the next year. This suggests a possible upside of 54.2% from the stock's current price. View Analyst Price Targets for Fate Therapeutics.

What is the consensus analysts' recommendation for Fate Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 2 hold ratings, 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fate Therapeutics.

What are Wall Street analysts saying about Fate Therapeutics stock?

Here are some recent quotes from research analysts about Fate Therapeutics stock:
  • 1. HC Wainwright analysts commented, "Our $12 price target is based on a sum-of-the-parts analysis based on probability-adjusted revenue forecasts for ProTmune and FATE-NK100. We use the net present value of our revenue forecast through 2026, apply a 40% probability of success for 2Q18 fully diluted net cash estimate of $0.84/share to arrive at our $12 price target. We value the early stage pipeline and Juno collaboration at $2.32/share. We assume a 25% discount rate for the NPV of the pipeline and a P/S multiple of 4x." (8/7/2018)
  • 2. According to Zacks Investment Research, "Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California. " (8/6/2018)

Who are some of Fate Therapeutics' key competitors?

Who are Fate Therapeutics' key executives?

Fate Therapeutics' management team includes the folowing people:
  • Mr. J. Scott Wolchko, Founder, CEO, Pres, Principal Financial Officer, Principal Accounting Officer & Director (Age 48)
  • Dr. Daniel D. Shoemaker, Chief Scientific Officer (Age 50)
  • Dr. Chris M. Storgard, Chief Medical Officer (Age 52)
  • Ms. Cindy R. Tahl, Gen. Counsel & Corp. Sec. (Age 45)
  • Mr. Jim Beitel M.B.A., Sr. VP of Corp. Devel.

Has Fate Therapeutics been receiving favorable news coverage?

News headlines about FATE stock have trended somewhat positive recently, Accern reports. Accern identifies negative and positive media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Fate Therapeutics earned a coverage optimism score of 0.13 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 46.65 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days. View Recent Headlines for Fate Therapeutics.

Who are Fate Therapeutics' major shareholders?

Fate Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (12.40%), BlackRock Inc. (6.15%), Millennium Management LLC (1.28%), Aquilo Capital Management LLC (1.09%), Victory Capital Management Inc. (0.97%) and Bank of New York Mellon Corp (0.55%). Company insiders that own Fate Therapeutics stock include Chris Storgard, Cindy Tahl, Daniel D Shoemaker and William H Rastetter. View Institutional Ownership Trends for Fate Therapeutics.

Which major investors are selling Fate Therapeutics stock?

FATE stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, EAM Investors LLC, Victory Capital Management Inc., TD Asset Management Inc. and Hochman Cole Investment Advisors Inc.. Company insiders that have sold Fate Therapeutics company stock in the last year include Cindy Tahl and Daniel D Shoemaker. View Insider Buying and Selling for Fate Therapeutics.

Which major investors are buying Fate Therapeutics stock?

FATE stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Aquilo Capital Management LLC, BlackRock Inc., Vident Investment Advisory LLC, Canada Pension Plan Investment Board, Alps Advisors Inc., Swiss National Bank and Strs Ohio. Company insiders that have bought Fate Therapeutics stock in the last two years include Chris Storgard and William H Rastetter. View Insider Buying and Selling for Fate Therapeutics.

How do I buy shares of Fate Therapeutics?

Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Fate Therapeutics' stock price today?

One share of FATE stock can currently be purchased for approximately $10.84.

How big of a company is Fate Therapeutics?

Fate Therapeutics has a market capitalization of $614.32 million and generates $4.11 million in revenue each year. The biopharmaceutical company earns $-42,950,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Fate Therapeutics employs 80 workers across the globe.

How can I contact Fate Therapeutics?

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected]


MarketBeat Community Rating for Fate Therapeutics (NASDAQ FATE)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  269 (Vote Outperform)
Underperform Votes:  146 (Vote Underperform)
Total Votes:  415
MarketBeat's community ratings are surveys of what our community members think about Fate Therapeutics and other stocks. Vote "Outperform" if you believe FATE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FATE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/20/2018 by MarketBeat.com Staff

Featured Article: Growth Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel